Exact Sciences (EXAS) announced an expanded partnership with Humana (HUM) to enhance access to colorectal cancer screening. Through the partnership, the Cologuard Plus test will be available as an in-network service for eligible Humana Medicare Advantage members nationwide beginning in August. Humana, the fourth largest private insurer in the United States, has approximately 5.8M Medicare Advantage members.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Buy Rating for Exact Sciences Driven by Promising CRC Screening Test and Favorable Market Outlook
- Exact Sciences’ Innovative PCR-Based Blood Test Positions Company for Market Leadership in Colorectal Cancer Screening
- Exact Sciences’ Oncodetect MRD Assay Gains Medicare Coverage, Boosting Long-Term Revenue Potential Amid Competitive Market
- Patent board invalidates Exact Sciences patent for stool samples
- Exact Sciences’ Growth Potential Bolstered by Medicare Coverage and Strategic Investments
